Company Announcements

Board Committee Changes

Source: RNS
RNS Number : 2581B
AstraZeneca PLC
30 September 2022

30 September 2022 10:30 BST



Remuneration Committee Chair Appointment


AstraZeneca PLC today announced the appointment of Sheri McCoy, Non-Executive Director, as Chair of the Remuneration Committee.  Sheri has served as a member of the Remuneration Committee since July 2018.


Sheri will succeed Michel Demaré who will step down as Chair of the Remuneration Committee following his recent appointment as Chair-designate of the Board.  He will remain a member of the Committee.


Sheri will also become a member of the Nomination and Governance Committee.


These Remuneration Committee and Nomination and Governance Committee changes are effective from 1 December 2022.  As previously announced, Michel Demaré will become Chair of the Board at the end of the Company's Annual General Meeting in April 2023.





Biography and photograph:



AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.



For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.



Adrian Kemp
Company Secretary

AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.